Insider Makes Significant Stock buy in G1 Therapeutics (GTHX) Shares Breaks neutral Trend of Last 90 Days

Wednesday, November 15, 2017 10:15 PM ET

Insider Makes Significant Stock buy in G1 Therapeutics (GTHX) Shares Breaks neutral Trend of Last 90 Days

There was significant buying activity in G1 Therapeutics shares by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Fredric N Eshelman, 10% Owner and Director — acquired 250,000 shares in the company having a market value of approximately $4,932,500. This is the first insider buy/sell trade in the past 90 days.

The level of buy-sell trading at G1 Therapeutics is near the 271 member peer company average. The Bio Therapeutic Drugs peer group saw 329 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares per buy/sell trade transacted by G1 Therapeutics insiders is higher. Within the peer group there were 32,142,994 shares purchased and 20,985,363 shares sold with company insiders having bought 55,236 shares on average.

The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.